부산대학교 도서관

Objective To examine whether a weight loss intervention programme improves RA disease activity and/or musculoskeletal ultrasound synovitis measures in obese RA patients. Methods We conducted a proof-of-concept, 12-week, single-blind, randomized controlled trial of obese RA patients (BMI ≥ 30) with 28-joint DAS (DAS28)  ≥ 3.2 and with evidence of power Doppler synovitis. Forty patients were randomized to the diet intervention (n  = 20) or control group (n  = 20). Diet intervention consisted of a hypocaloric diet of 1000–1500 kcal/day and high protein meal replacements. Co-primary outcomes included change in DAS28 and power Doppler ultrasound (PDUS)-34. Clinical disease activity, imaging, biomarkers, adipokines and patient-reported outcomes were monitored throughout the trial. Recruitment terminated early. All analyses were based on intent-to-treat for a significance level of 0.05. Results The diet intervention group lost an average 9.5 kg/patient, while the control group lost 0.5 kg (P  < 0.001). Routine Assessment of Patient Index Data 3 (RAPID3) improved, serum leptin decreased and serum adiponectin increased significantly within the diet group and between the groups (all P  < 0.03). DAS28 decreased, 5.2 to 4.2, within the diet group (P  < 0.001; −0.51 [95% CI −1.01, 0.00], P  = 0.056, between groups). HAQ-Disability Index (HAQ-DI) improved significantly within the diet group (P  < 0.04; P  = 0.065 between group). Ultrasound measures and the multi-biomarker disease activity score did not differ between groups (PDUS-34 −2.0 [95% CI −7.00, 3.1], P  = 0.46 between groups). Conclusion Obese RA patients on the diet intervention achieved weight loss. There were significant between group improvements for RAPID3, adiponectin and leptin levels, and positive trends for DAS28 and HAQ-DI. Longer-term, larger weight loss studies are needed to validate these findings, and will allow for further investigative work to improve the clinical management of obese RA patients. Trial registration ClinicalTrials.gov, https://clinicaltrials.gov , NCT02881307 [ABSTRACT FROM AUTHOR]